| scholarly article | Q13442814 |
| P2093 | author name string | Fisher C | |
| Woodgett JR | |||
| Evan G | |||
| Littlewood T | |||
| Vousden K | |||
| Pulverer BJ | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phosphorylation | Q242736 |
| P304 | page(s) | 59-70 | |
| P577 | publication date | 1994-01-01 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo | |
| P478 | volume | 9 |
| Q36553239 | A link between increased transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-Myc transactivation domain |
| Q35000701 | A novel phosphatidylinositol 3-kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genes |
| Q55481055 | A polymorphic variant of human c-Myc: Asn11-->Ser. |
| Q34609728 | A tumor suppressor role for PP2A-B56alpha through negative regulation of c-Myc and other key oncoproteins |
| Q34540779 | Ampelopsin induces apoptosis by regulating multiple c-Myc/S-phase kinase-associated protein 2/F-box and WD repeat-containing protein 7/histone deacetylase 2 pathways in human lung adenocarcinoma cells |
| Q35855075 | Apparent uncoupling of oncogenicity from fibroblast transformation and apoptosis in a mutant myc gene transduced by feline leukemia virus |
| Q24676501 | Astrocyte elevated gene-1: recent insights into a novel gene involved in tumor progression, metastasis and neurodegeneration |
| Q35310856 | Autoregulatory suppression of c-Myc by miR-185-3p |
| Q37214654 | Burkitt's lymphoma-associated c-Myc mutations converge on a dramatically altered target gene response and implicate Nol5a/Nop56 in oncogenesis |
| Q28265732 | CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis |
| Q38868844 | Cdk5-mediated phosphorylation of c-Myc on Ser-62 is essential in transcriptional activation of cyclin B1 by cyclin G1. |
| Q38836923 | Chaperone-mediated autophagy prevents cellular transformation by regulating MYC proteasomal degradation. |
| Q37100081 | Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma |
| Q39610851 | Complementation of defective colony-stimulating factor 1 receptor signaling and mitogenesis by Raf and v-Src |
| Q33608508 | Controlling the Master: Chromatin Dynamics at the MYC Promoter Integrate Developmental Signaling |
| Q33890400 | Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc. |
| Q35140193 | Diffuse large B-cell lymphoma: insights gained from gene expression profiling |
| Q33964663 | Disruption of Myc-tubulin interaction by hyperphosphorylation of c-Myc during mitosis or by constitutive hyperphosphorylation of mutant c-Myc in Burkitt's lymphoma |
| Q24624069 | GSK-3: tricks of the trade for a multi-tasking kinase |
| Q37483862 | GSK-3β controls NF-kappaB activity via IKKγ/NEMO. |
| Q40963450 | GSK3 as a Sensor Determining Cell Fate in the Brain |
| Q34374129 | GSK3 takes centre stage more than 20 years after its discovery |
| Q39801525 | GSK3beta is a negative regulator of the transcriptional coactivator MAML1. |
| Q41863937 | Gain-of-Function Mutations in the Toll-Like Receptor Pathway: TPL2-Mediated ERK1/ERK2 MAPK Activation, a Path to Tumorigenesis in Lymphoid Neoplasms? |
| Q34692767 | Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection |
| Q34331166 | Glycosylation of the c-Myc transactivation domain |
| Q36663762 | Hierarchical phosphorylation at N-terminal transformation-sensitive sites in c-Myc protein is regulated by mitogens and in mitosis |
| Q35529775 | Identification of c-MYC SUMOylation by mass spectrometry |
| Q36622715 | Immortalization and transformation of human mammary epithelial cells by a tumor-derived Myc mutant |
| Q33374007 | Immortalization of human neural stem cells with the c-myc mutant T58A. |
| Q33965061 | Induction of cell cycle progression and acceleration of apoptosis are two separable functions of c-Myc: transrepression correlates with acceleration of apoptosis |
| Q39937926 | Inhibition of GSK-3beta promotes survival and proliferation of megakaryocytic cells through a beta-catenin-independent pathway |
| Q35875611 | Integrin signalling and the cellular response to ionizing radiation. |
| Q33836755 | MYC Deregulation in Primary Human Cancers. |
| Q39406924 | MYC Modulation around the CDK2/p27/SKP2 Axis |
| Q38193043 | MYC degradation |
| Q42117553 | Maintenance of constitutive IkappaB kinase activity by glycogen synthase kinase-3alpha/beta in pancreatic cancer |
| Q33521691 | Mechanisms of c-myc degradation by nickel compounds and hypoxia |
| Q92490663 | Mission Possible: Advances in MYC Therapeutic Targeting in Cancer |
| Q39648270 | Modulation of T-lymphocyte development, growth and cell size by the Myc antagonist and transcriptional repressor Mad1. |
| Q35204486 | Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. |
| Q33997741 | Myc proteins as therapeutic targets |
| Q35920494 | Myc proteins in brain tumor development and maintenance |
| Q28241326 | Negative control of the Myc protein by the stress-responsive kinase Pak2 |
| Q37201479 | Neuroblastoma and MYCN |
| Q34305847 | New insights into the mechanisms of embryonic stem cell self-renewal under hypoxia: a multifactorial analysis approach. |
| Q35554311 | Novel agent nitidine chloride induces erythroid differentiation and apoptosis in CML cells through c-Myc-miRNAs axis |
| Q64115578 | Nuclear ERK: Mechanism of Translocation, Substrates, and Role in Cancer |
| Q33925043 | Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1. |
| Q37686796 | PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression |
| Q33316851 | Phosphatidylinositol 3-kinase signaling in proliferating cells maintains an anti-apoptotic transcriptional program mediated by inhibition of FOXO and non-canonical activation of NFkappaB transcription factors |
| Q34801773 | Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland. |
| Q34743616 | Pin1 regulates the dynamics of c-Myc DNA binding to facilitate target gene regulation and oncogenesis |
| Q33742040 | Point Mutations in c-Myc Uncouple Neoplastic Transformation from Multiple Other Phenotypes in Rat Fibroblasts |
| Q58114009 | Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals |
| Q43240765 | Protein phosphatase 2A regulatory subunit B56alpha associates with c-myc and negatively regulates c-myc accumulation |
| Q41493079 | Protein phosphatase 2A stabilizes human securin, whose phosphorylated forms are degraded via the SCF ubiquitin ligase |
| Q24538036 | Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells |
| Q37184834 | Repeated electroconvulsive seizure induces c-Myc down-regulation and Bad inactivation in the rat frontal cortex |
| Q47572600 | Stabilization of the c-Myc Protein by CAMKIIγ Promotes T Cell Lymphoma |
| Q34835596 | The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation |
| Q37210931 | The GSK-3/beta-catenin-signalling axis in smooth muscle and its relationship with remodelling |
| Q36099076 | The Kaposi's sarcoma-associated herpesvirus LANA protein stabilizes and activates c-Myc |
| Q33967079 | The Max network gone mad. |
| Q41036174 | The Overexpression of CARM1 Promotes Human Osteosarcoma Cell Proliferation through the pGSK3β/β-Catenin/cyclinD1 Signaling Pathway |
| Q33963949 | The c-Myc transactivation domain is a direct modulator of apoptotic versus proliferative signals |
| Q34373258 | Therapeutic Targeting of Myc. |
| Q40427891 | Transcriptional Regulation: Flipping the Myc switch |
| Q34066202 | Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes |
| Q37988976 | Two sides of the Myc-induced DNA damage response: from tumor suppression to tumor maintenance |
| Q35001234 | What Are the bona fide GSK3 Substrates? |
| Q28535037 | Wogonin has multiple anti-cancer effects by regulating c-Myc/SKP2/Fbw7α and HDAC1/HDAC2 pathways and inducing apoptosis in human lung adenocarcinoma cell line A549 |
| Q33962550 | c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells |
| Q39576244 | myc boxes, which are conserved in myc family proteins, are signals for protein degradation via the proteasome |
Search more.